Fiscal period | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
Period End Date | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 |
Net Sales | 7,678.60 | 7,394.20 | 6,939.90 | 7,836.20 | 7,024.50 | 7,982.20 | 7,932.90 | 7,824.10 | 7,683.90 | 5,997.80 |
Total Revenues | 7,678.60 | 7,394.20 | 6,939.90 | 7,836.20 | 7,024.50 | 7,982.20 | 7,932.90 | 7,824.10 | 7,683.90 | 5,997.80 |
Cost of Products Sold | 2,191.20 | 2,083.80 | 2,019.50 | 2,341.00 | 2,128.30 | 2,252.60 | 2,271.90 | 2,132.90 | 2,381.80 | 1,800.60 |
Gross Profit | -- | -- | -- | -- | -- | -- | 5,661.00 | 5,691.20 | 5,302.10 | 4,197.20 |
Goodwill impairment | -- | -- | 292.80 | 16.30 | 645.00 | 70.10 | 979.70 | 304.70 | -- | -- |
Intangible asset amortization | 591.90 | 561.50 | 526.80 | 615.70 | 597.60 | 584.30 | 595.90 | 603.90 | 565.90 | 337.40 |
Research and development | 437.40 | 458.70 | 406.00 | 497.20 | 372.00 | 449.30 | 391.70 | 367.40 | 365.60 | 268.80 |
In-process research and development | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Selling, general and administrative | 2,929.80 | 2,838.90 | 2,761.70 | 3,323.90 | 3,177.80 | 3,343.80 | 3,379.30 | 2,973.90 | 2,932.90 | 2,284.20 |
Acquisition, integration and other expense | 23.60 | 21.70 | 11.40 | 79.80 | 23.80 | 12.20 | 133.70 | -- | -- | -- |
Restructuring and other cost reduction initiatives | 219.00 | 151.90 | 191.60 | 129.10 | 116.90 | 50.00 | -- | -- | -- | -- |
Special items | -- | -- | -- | -- | -- | -- | -- | (633.10) | (611.80) | (831.80) |
Settlement | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Certain claims | -- | -- | -- | -- | -- | -- | -- | -- | -- | (7.70) |
Net curtailment and settlement | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Quality remediation | -- | -- | (33.80) | (53.10) | (50.90) | (82.40) | (146.90) | -- | -- | -- |
Operating Expenses | 6,392.90 | 6,116.50 | 6,243.60 | 7,056.10 | 7,112.30 | 6,844.70 | 7,899.10 | 7,015.90 | 6,858.00 | 5,530.50 |
Operating Income (Loss) | 1,285.70 | 1,277.70 | 696.30 | 780.10 | (87.80) | 1,137.50 | 33.80 | 808.20 | 825.90 | 467.30 |
Interest expense, net | 218.00 | 201.20 | 164.80 | 208.40 | 212.00 | 226.90 | 289.30 | 327.50 | 357.90 | 286.60 |
Interest income (expense) | -- | -- | -- | -- | -- | -- | -- | 2.20 | 2.90 | 9.40 |
Loss on early extinguishment of debt | -- | -- | -- | (165.10) | -- | -- | -- | -- | -- | -- |
Other expense | (31.10) | (9.30) | (128.00) | 11.80 | 25.40 | (4.80) | (15.60) | (18.30) | (71.30) | (36.90) |
Earnings before income taxes and minority interest | 1,036.60 | 1,067.30 | 403.50 | 418.40 | (274.40) | 905.80 | (271.10) | 464.60 | 399.60 | 153.20 |
Current Federal | 4.40 | -- | 175.30 | 32.20 | (96.10) | 65.50 | (46.20) | 438.50 | 134.20 | 55.80 |
Current State | 20.90 | -- | 16.10 | 10.40 | 4.60 | 9.80 | 24.40 | 2.40 | 12.40 | 18.90 |
Current Foreign | 153.80 | -- | (14.70) | 123.40 | (57.50) | 237.70 | 116.60 | (13.70) | 101.60 | 96.30 |
Deferred Federal | (59.70) | -- | (74.80) | (115.80) | (24.20) | (90.20) | 37.90 | (1,728.50) | (108.50) | (120.60) |
Deferred State | (12.30) | -- | 1.60 | (21.60) | (11.50) | (4.20) | (8.80) | (95.50) | 2.30 | (20.00) |
Deferred Foreign | 24.30 | -- | 8.80 | (12.30) | 47.70 | (444.30) | (15.70) | 48.00 | (47.00) | (23.40) |
Provision for Income Tax | 131.40 | 42.20 | 112.30 | 16.30 | (137.00) | (225.70) | 108.20 | (1,348.80) | 95.00 | 7.00 |
Minority interest | -- | -- | 1.00 | -- | -- | -- | -- | -- | -- | -- |
Net Earnings from Continuing Operations of Zimmer Biomet Holdings, Inc | 905.20 | 1,025.10 | 290.20 | -- | -- | -- | -- | -- | -- | -- |
(Loss) Earnings from discontinued operations, net of taxes | -- | -- | (58.80) | -- | -- | -- | -- | -- | -- | -- |
Earnings before cumulative effect of change in accounting principle | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Cumulative Effect of Change in Accounting Principle | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Net Earnings | 905.20 | 1,025.10 | 231.40 | 402.10 | (137.40) | 1,131.50 | (379.30) | 1,813.40 | 304.60 | 146.20 |
Less : Net earnings attributable to noncontrolling interest | 1.50 | 1.10 | -- | 0.50 | 1.50 | (0.10) | (0.10) | (0.40) | (1.30) | (0.80) |
Net Income (loss) Available to Common Shareholders | 903.80 | 1,024.00 | 231.40 | 401.60 | (138.90) | 1,131.60 | (379.20) | 1,813.80 | 305.90 | 147.00 |
Earnings before cumulative effect of change in accounting principle | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Earnings from continuing operations | 4.45 | 4.91 | 1.38 | -- | -- | -- | -- | -- | -- | -- |
(Loss) earnings from discontinued operations | -- | -- | (0.28) | -- | -- | -- | -- | -- | -- | -- |
Cumulative effect of change in accounting principle, net of tax | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Net Earnings Per Share (Basic) | 4.45 | 4.91 | 1.10 | 1.93 | (0.67) | 5.52 | (1.86) | 8.98 | 1.53 | 0.78 |
Earnings before cumulative effect of change in accounting principle | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Earnings from continuing operations | 4.43 | 4.88 | 1.38 | -- | -- | -- | -- | -- | -- | -- |
(Loss) earnings from discontinued operations | -- | -- | (0.28) | -- | -- | -- | -- | -- | -- | -- |
Cumulative effect of change in accounting principle, net of tax | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Net Earnings Per Share (Diluted) | 4.43 | 4.88 | 1.10 | 1.91 | (0.67) | 5.47 | (1.86) | 8.90 | 1.51 | 0.77 |
Weighted Average Shares Outstanding (Basic) | 203.10 | 208.70 | 209.60 | 208.60 | 207.00 | 205.10 | 203.50 | 201.90 | 200.00 | 187.40 |
Weighted Average Shares Outstanding (Diluted) | 203.90 | 209.70 | 210.30 | 210.40 | 207.00 | 206.70 | 203.50 | 203.70 | 202.40 | 189.80 |